Thalidomide supplier | CasNO.50-35-1

Name
Thalidomide
EINECS 200-031-1
CAS No. 50-35-1
Article Data47
CAS DataBase
Density 1.503 g/cm³
Solubility <0.1 g/100 mL at 22 °C in water
Melting Point 269-271 °C
Formula C₁₃H₁₀N₂O₄
Boiling Point 509.7 °C at 760 mmHg
Molecular Weight 258.233
Flash Point 262.1 °C
Transport Information UN 2811 6.1/PG 3
Appearance white solid
Safety 53-22-26-36/37/39-45
Risk Codes 46-61-21-25-62
Molecular Structure
Hazard Symbols T
Synonyms Phthalimide,N-(2,6-dioxo-3-piperidyl)- (6CI,7CI,8CI);1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline;3-Phthalimidoglutarimide;Celgene;Contergan;Distaval;K 17;Kevadon;Myrin;N-Phthaloylglutamimide;Pantosediv;Quetimid;Sauramide;Softenil;Suaramide;Talimol;Thalomid;a-(N-Phthalimido)glutarimide;a-N-Phthalylglutaramide;a-Phthalimidoglutarimide;
PSA 83.55000
LogP 0.35450

Synthetic route

: 85-44-9
phthalic anhydride

: 24666-56-6
rac-α-aminoglutarimide hydrochloride

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With acetic acid; triethylamine for 3h; Temperature; Reagent/catalyst; Concentration; Reflux;	95%

: 3343-29-1
(S)-2-phthalimidoglutaramic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With dmap; 1,1'-carbonyldiimidazole In tetrahydrofuran for 16h; Reflux; Inert atmosphere;	91%

: 85-44-9
phthalic anhydride

: 31140-42-8
(RS)-(2,6-dioxopiperidin-3-yl)carbamic acid tert-butyl ester

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With 2,2,2-trifluoroethanol at 150℃; for 2h; Reagent/catalyst; Microwave irradiation;	91%
In 2,2,2-trifluoroethanol at 150℃; for 2h; Solvent;	91%
With sodium acetate; acetic acid for 6h; Reflux;

: 85-44-9
phthalic anhydride

A: 136918-14-4
phthalimide

B: 50-35-1
thalidomide

Conditions

Conditions	Yield
With Glutamic acid; ammonium acetate at 150℃; for 0.166667h; Reagent/catalyst; Microwave irradiation; Sealed tube; Green chemistry;	A 90% B 7%

: 201230-82-2
carbon monoxide

: 2353-44-8
(+/-)-α-aminoglutarimide

: 583-53-9
1,2-dibromobenzene

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With palladium diacetate; triethylamine; catacxium A In N,N-dimethyl acetamide at 100℃; under 22502.3 Torr; for 30h; Autoclave; Inert atmosphere;	87%

...Expand

: 85-44-9
phthalic anhydride

: 617-65-2
Glutamic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With dmap; ammonium chloride at 150℃; for 0.166667h; Microwave irradiation; Sealed tube; Green chemistry;	86%

: 340-90-9
N-phthaloyl-L-glutamic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With thiourea for 0.25h; Microwave irradiation;	85%

: 3343-28-0
N-phthaloylglutamic acid anhydride

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With urea at 170 - 180℃; for 0.75h;	75%
With urea at 180℃;	70%
Stage #1: N-phthaloylglutamic acid anhydride With ammonia In N,N-dimethyl-formamide at 25℃; for 14h; Stage #2: With 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 100℃; for 1h;	68.3%

: 671787-01-2
2-[2,6-dioxo-5-(toluene-4-sulfonyl)-piperidin-3-yl]-isoindole-1,3-dione

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With sodium amalgam at 20℃; for 4h;	72%

: 56-85-9
L-glutamine

: 131-11-3
phthalic acid dimethyl ester

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Stage #1: L-glutamine; phthalic acid dimethyl ester With pyridine at 20 - 85℃; for 6h; Stage #2: With 1,1'-carbonyldiimidazole at 40℃; for 2h; Stage #3: With hydrogenchloride In ethanol; water at 5 - 25℃; for 4h; pH=7; Product distribution / selectivity;	72%

: 85-44-9
phthalic anhydride

: 56-85-9
L-glutamine

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Stage #1: phthalic anhydride; L-glutamine In ISOPROPYLAMIDE at 20 - 80℃; for 6h; Stage #2: With 1,1'-carbonyldiimidazole In ISOPROPYLAMIDE at 20 - 90℃; for 4h; Product distribution / selectivity;	71%
Stage #1: phthalic anhydride; L-glutamine In 1-methyl-pyrrolidin-2-one at 20 - 80℃; for 6h; Stage #2: With 1,1'-carbonyldiimidazole In 1-methyl-pyrrolidin-2-one at 20 - 90℃; for 4h; Product distribution / selectivity;	65%
Stage #1: phthalic anhydride; L-glutamine In DMF (N,N-dimethyl-formamide) at 20 - 80℃; for 6h; Stage #2: With 1,1'-carbonyldiimidazole In DMF (N,N-dimethyl-formamide) at 20 - 90℃; for 4h; Product distribution / selectivity;	63%

: 7607-72-9
2-phthalimidoglutaramic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With 1,1'-carbonyldiimidazole In ISOPROPYLAMIDE at 20 - 90℃; for 4h; Product distribution / selectivity;	71%
With 1,1'-carbonyldiimidazole In 1-methyl-pyrrolidin-2-one at 20 - 90℃; for 4h; Product distribution / selectivity;	65%
With 1,1'-carbonyldiimidazole In dimethyl sulfoxide at 20 - 90℃; for 4h; Product distribution / selectivity;	62%

: 6349-98-0
N-phthalylglutamic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With ammonium acetate In diphenylether at 170 - 175℃; for 0.75h; Reagent/catalyst; Solvent; Temperature;	65.57%
With urea In 5,5-dimethyl-1,3-cyclohexadiene for 12h; Solvent; Temperature; Reflux;	42.5%

: 31140-42-8
(RS)-(2,6-dioxopiperidin-3-yl)carbamic acid tert-butyl ester

: 88-99-3
benzene-1,2-dicarboxylic acid

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With 2,2,2-trifluoroethanol at 150℃; for 2h; Microwave irradiation;	62%

: 56-85-9
L-glutamine

: 88-95-9
Phthaloyl dichloride

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Stage #1: L-glutamine; Phthaloyl dichloride With pyridine at 10 - 15℃; for 4h; Stage #2: With 1,1'-carbonyldiimidazole at 20℃; for 4h; Stage #3: With hydrogenchloride In water at 5 - 20℃; for 4h; pH=7; Product distribution / selectivity;	58%

: 85-44-9
phthalic anhydride

: (RS)-2,6-dioxopiperidin-3-yl-ammonium trifluoroacetate

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With triethylamine In tetrahydrofuran at 80℃; for 24h;	55%
With triethylamine In tetrahydrofuran for 48h; Heating / reflux;	54%

: 108-24-7
acetic anhydride

: 7607-72-9
2-phthalimidoglutaramic acid

: 50-35-1
thalidomide

: 57-13-6
urea

: 3343-28-0
N-phthaloylglutamic acid anhydride

: 50-35-1
thalidomide

Conditions

Conditions	Yield
at 170 - 180℃;

: 85-44-9
phthalic anhydride

: 56-85-9
L-glutamine

A: 50-35-1
thalidomide

B: 149-87-1
Pyroglutamic acid

Conditions

Conditions	Yield
for 0.316667h; Microwave irradiation;

...Expand

: 2-aminoacetic acid-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-2,6-dioxo-piperidin-1-yl]methyl ester hydrochloride

A: 50-00-0
formaldehyd

B: 23297-34-9
glycinate

C: 50-35-1
thalidomide

Conditions

Conditions	Yield
With phosphate buffer In water at 37℃; pH=7.4; Kinetics;

...Expand

: 2-methylamino(propionic acid)-[3-(1,3-dihydro-1,3-dioxo-2H-isoindole-2-yl)-2,6-di-oxo-piperidine-1-yl-methyl]ester hydrochloride

A: 50-00-0
formaldehyd

B: 50-35-1
thalidomide

C: (S)-2-Methylamino-propionic acid anion

Conditions

Conditions	Yield
With phosphate buffer In water at 37℃; pH=7.4; Kinetics;

...Expand

: 2-amino-3-methylbutyric acid-[3-(1,3-dihydro-1,3-dioxo-2H-isoindole-2-yl)-2,6-dioxo-piperidine-1-yl-methyl]ester hydrochloride

A: 50-00-0
formaldehyd

B: 50-35-1
thalidomide

C: 17333-21-0
L-valinate

Conditions

Conditions	Yield
With phosphate buffer In water at 37℃; pH=7.4; Kinetics;

...Expand

: 222713-07-7
2-[1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl]isoindoline-1,3-dione

: 50-35-1
thalidomide

Conditions

Conditions	Yield
With ammonium cerium(IV) nitrate In acetonitrile at 20℃; for 5h;	34 mg
With ammonium cerium(IV) nitrate In water; acetonitrile for 5h;	34 mg

: 24249-89-6
ethyl 2-(1,3-dioxoisoindolin-2-yl)acrylate

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 72 percent / Na/Hg / 4 h / 20 °C View Scheme

: 136918-14-4
phthalimide

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1.1: triphenylphosphine; sodium acetate / toluene / 0.17 h / Heating 1.2: 78 percent / acetic acid / toluene / 18 h / Heating 2.1: sodium hydride / tetrahydrofuran / 0.08 h / 20 °C 2.2: 58 percent / tetrahydrofuran / 0.33 h / Heating 3.1: 6 percent sodium amalgam; sodium phosphate / methanol / 1 h / 20 °C 4.1: 34 mg / ceric ammonium nitrate / acetonitrile; H2O / 5 h View Scheme

Yield

Multi-step reaction with 4 steps
1.1: triphenylphosphine; sodium acetate / toluene / 0.17 h / Heating
1.2: 78 percent / acetic acid / toluene / 18 h / Heating
2.1: sodium hydride / tetrahydrofuran / 0.08 h / 20 °C
2.2: 58 percent / tetrahydrofuran / 0.33 h / Heating
3.1: 6 percent sodium amalgam; sodium phosphate / methanol / 1 h / 20 °C
4.1: 34 mg / ceric ammonium nitrate / acetonitrile; H2O / 5 h
View Scheme

: 26878-24-0
methyl 2-phthalimidoacrylate

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: sodium hydride / tetrahydrofuran / 0.08 h / 20 °C 1.2: 58 percent / tetrahydrofuran / 0.33 h / Heating 2.1: 6 percent sodium amalgam; sodium phosphate / methanol / 1 h / 20 °C 3.1: 34 mg / ceric ammonium nitrate / acetonitrile; H2O / 5 h View Scheme

: 485817-55-8
1-p-methoxybenzyl-3-phthalimido-5-(p-toluenesulfonyl)piperidine-2,6-dione

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 6 percent sodium amalgam; sodium phosphate / methanol / 1 h / 20 °C 2: 34 mg / ceric ammonium nitrate / acetonitrile; H2O / 5 h View Scheme
Multi-step reaction with 2 steps 1: Na2HPO4; 6 percent sodium amalgam / methanol / 1 h / 20 °C 2: 34 mg / aq. ceric ammonium nitrate / acetonitrile / 5 h / 20 °C View Scheme

: 485817-54-7
3-amino-1-(4-methoxy-benzyl)-5-(toluene-4-sulfonyl)-piperidine-2,6-dione

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: 450 mg / Et3N; 4 A molecular sieves / tetrahydrofuran / 2 h / Heating 2: Na2HPO4; 6 percent sodium amalgam / methanol / 1 h / 20 °C 3: 34 mg / aq. ceric ammonium nitrate / acetonitrile / 5 h / 20 °C View Scheme

: 485817-52-5
1-p-methoxybenzyl-3-tert-butoxycarbonylamino-5-(p-toluenesulfonyl)-piperidine-2,6-dione

: 50-35-1
thalidomide

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: TFA / CH2Cl2 / 0.5 h / 20 °C 2: 450 mg / Et3N; 4 A molecular sieves / tetrahydrofuran / 2 h / Heating 3: Na2HPO4; 6 percent sodium amalgam / methanol / 1 h / 20 °C 4: 34 mg / aq. ceric ammonium nitrate / acetonitrile / 5 h / 20 °C View Scheme

: 50-35-1
thalidomide

: 5538-51-2
O-acetylsalicyloyl chloride

: 2-acetoxy-N-(2,6-dioxopiperidin-3-yl)benzamide

Conditions

Conditions	Yield
With triethylamine In chloroform at 0 - 20℃;	98%

: 123-91-1
1,4-dioxane

: 1398179-24-2
ethyl 2-(2-bromophenyl)-2-diazoacetate

: 50-35-1
thalidomide

: ethyl 2-(2-bromophenyl)-2-(2-(2-(3-(1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)ethoxy)ethoxy)acetate

Conditions

Conditions	Yield
With potassium carbonate at 80℃; for 12h; Inert atmosphere; Schlenk technique;	98%

...Expand

: 50-35-1
thalidomide

A: 2614-06-4
(R)-thalidomide

B: 841-67-8
(S)-thalidomide

Conditions

Conditions	Yield
With 2C8H8N5O2(1-)*Cu(2+) In acetonitrile at 25℃; Resolution of racemate;	A 96% B 78%
With N-[(S)-1-phenylethyl]carbamoyl-derivatized cyclofructan-6 column In ethanol; n-heptane; trifluoroacetic acid at 20℃; Resolution of racemate;
With chiral Ceramosphere RU-2 In methanol Resolution of racemate;

: 50-35-1
thalidomide

: 373-68-2
tetramethylammonium fluoride

: 42472-93-5
2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
In 1-methyl-pyrrolidin-2-one at 160℃; for 12h;	92%

: 24424-99-5
di-tert-butyl dicarbonate

: 50-35-1
thalidomide

: 220460-69-5
1,3-dioxo-2-(1-tert.-butoxycarbonyl-2,6-dioxopiperidin-3-yl)isoindoline

Conditions

Conditions	Yield
With dmap In 1,4-dioxane	90%
With 2-(Dimethylamino)pyridine In 1,4-dioxane

: 50-35-1
thalidomide

: 58585-25-4
3-(1-hydroxy-3-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

Conditions

Conditions	Yield
With acetic acid; zinc at 90℃; for 0.166667h;	87%
With aluminium amalgam; water; acetic acid In ethanol for 3h; Heating;

: 50-35-1
thalidomide

: 106-96-7
propargyl bromide

: 2-[2,6-dioxo-1-(prop-2-yn-1-yl)piperidin-3-yl]isoindoline-1,3-dione

Conditions

Conditions	Yield
Stage #1: thalidomide With potassium carbonate In acetone at 20℃; for 0.166667h; Stage #2: propargyl bromide In acetone; toluene at 20℃; for 48h;	87%

: 50-35-1
thalidomide

: 113738-22-0
tosylethylazide

: (±)-2-(1-(2-azidoethyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
Stage #1: thalidomide With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 0.25h; Stage #2: tosylethylazide In N,N-dimethyl-formamide; mineral oil at 60℃; for 18h;	84%

: 50-35-1
thalidomide

: 107-82-4
i-pentyl bromide

: 2-(1-(4-methylpentyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
Stage #1: thalidomide With sodium hydride In dimethyl sulfoxide; mineral oil for 0.25h; Inert atmosphere; Stage #2: i-pentyl bromide In dimethyl sulfoxide; mineral oil at 20℃; Inert atmosphere;	84%

: 42599-24-6
E-styryl iodide

: N-(quinolin-8-yl)but‐3‐enamide

: 50-35-1
thalidomide

: (E)-3-((3-(1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl)-5-phenyl-N-(quinolin-8-yl)pent-4-enamide

Conditions

Conditions	Yield
With palladium diacetate; potassium hydrogencarbonate at 100℃; regioselective reaction;	83%

...Expand

: 63281-98-1
(Z)-1-bromo-4-hexene

: 50-35-1
thalidomide

: C19H20N2O4

Conditions

Conditions	Yield
Stage #1: thalidomide With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0℃; for 1h; Stage #2: (Z)-1-bromohex-4-ene In N,N-dimethyl-formamide; mineral oil at 0 - 20℃;	79%

: 50-35-1
thalidomide

: 107-82-4
i-pentyl bromide

: 2-(1-isopentyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 60℃; for 16h;	79%

: 762-49-2
2-fluoroethyl bromide

: 50-35-1
thalidomide

: (±)-2-(1-(2-fluoroethyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
Stage #1: thalidomide With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 0.5h; Stage #2: 2-fluoroethyl bromide In N,N-dimethyl-formamide at 20℃; for 72h;	77%

: 75-15-0
carbon disulfide

: 50-35-1
thalidomide

: C14H9N2O4S2(1-)

Conditions

Conditions	Yield
Stage #1: carbon disulfide; thalidomide In methanol at 0 - 5℃; for 4h; Stage #2: With sodium hydroxide In methanol for 8h;	74.6%

: 33657-49-7
chloromethyl n-butyrate

: 50-35-1
thalidomide

: 2-(1-butyroyloxymethyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
Stage #1: thalidomide With caesium carbonate In DMF (N,N-dimethyl-formamide) Stage #2: chloromethyl n-butyrate In DMF (N,N-dimethyl-formamide) at 20℃; for 20h;	74%

: 50-35-1
thalidomide

: 145945-21-7
(R,S)-2-(1-(hydroxymethyl)-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
With formaldehyd In water at 25℃; Reflux;	74%

: 50-35-1
thalidomide

: 1,3-dioxo-2-(2-oxo-6-thioxopiperidin-3-yl)isoindoline

Conditions

Conditions	Yield
With Lawessons reagent In toluene for 12h; Heating / reflux;	73%

: 50-35-1
thalidomide

: 74-88-4
methyl iodide

: 42472-93-5
2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Conditions

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 0 - 20℃; for 12h; Inert atmosphere;	72.3%

Thalidomide Chemical Properties

Molecular Structure of Thalidomide (CAS NO.50-35-1):

IUPAC Name: 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Molecular Formula: C₁₃H₁₀N₂O₄
Molecular Weight: 258.229500 g/mol
H bond acceptors: 6
H bond donors: 1
#Freely Rotating Bonds: 1
Polar Surface Area: 74.76Å²
Index of Refraction: 1.646
Molar Refractivity: 62.35 cm³
Molar Volume: 171.7 cm³
Surface Tension: 69.9 dyne/cm
Enthalpy of Vaporization: 78.04 kJ/mol
Vapour Pressure: 1.65E-10 mmHg at 25°C
Density: 1.503 g/cm³
Melting Point: 269-271 °C
Boiling Point: 509.7 °C at 760 mmHg
Flash Point: 262.1 °C
Water solubility: <0.1 g/100 mL at 22 °C
EINECS: 200-031-1
Categories: Intermediates & Fine Chemicals; Pharmaceuticals; API's; Cytokine signaling

Thalidomide History

One source have suggested that Thalidomide (CAS NO.50-35-1) had been developed under the direction of a Nazi scientist in 1944, other sources have suggested that it may have been first synthesised by British scientists at the University of Nottingham in 1949.

Thalidomide Toxicity Data With Reference

1.	cyt-hmn:lym 1 mg/L	AMSVAZ Acta Medica Scandinavica. 177 (1965),783.
2.	dns-rat-ipr 80 mg/kg	JPETAB Journal of Pharmacology and Experimental Therapeutics. 171 (1970),109.
3.	orl-rat LD50:113 mg/kg	TXAPA9 Toxicology and Applied Pharmacology. 14 (1969),515.
4.	skn-rat LD50:1550 mg/kg	TXAPA9 Toxicology and Applied Pharmacology. 14 (1969),515.
5.	orl-mus LD50:2000 mg/kg	LIFSAK Life Sciences. 3 (1964),721.
6.	ipr-mus LDLo:800 mg/kg	TXAPA9 Toxicology and Applied Pharmacology. 23 (1972),288.

Thalidomide Consensus Reports

EPA Genetic Toxicology Program.

Thalidomide Safety Profile

Safety Information of Thalidomide (CAS NO.50-35-1):
Hazard Codes: T
Risk Statements: 46-61-21-25-62
R46:May cause heritable genetic damage.
R61:May cause harm to the unborn child.
R21:Harmful in contact with skin.
R25 :Toxic if swallowed.
R62:Risk of impaired fertility.
Safety Statements: 53-22-26-36/37/39-45
S53:Avoid exposure - obtain special instructions before use.
S22:Do not breathe dust.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: TI4375000
HazardClass: 6.1(b)
PackingGroup: III
Poison by ingestion. Moderately toxic by skin contact and intraperitoneal routes. Human teratogenic effects by ingestion: developmental abnormalities of the musculoskeletal and cardiovascular systems. Experimental reproductive effects. Questionable carcinogen with experimental tumorigenic and teratogenic data. Human mutation data reported. It was commonly used as a prescription drug in Europe in the late 1950s and early 1960s. Its use was discontinued because it was discovered to cause serious congenital abnormalities in the fetus, notably amelia and phocomelia (absence or deformity of the limbs, including hands and feet) when taken by a woman during early pregnancy. When heated to decomposition it emits toxic fumes of NO_x. Used as a sedative and hypnotic.

Thalidomide Specification

Thalidomide , with CAS number of 50-35-1, can be called Phthalimide,N-(2,6-dioxo-3-piperidyl)- (6CI,7CI,8CI) ; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline ; 3-Phthalimidoglutarimide ; Contergan ; N-(2,6-Dioxo-3-piperidyl)phthalimide ; N-Phthaloylglutamimide ; a-(N-Phthalimido)glutarimide ; a-Phthalimidoglutarimide . It is a white powder. Thalidomide (CAS NO.50-35-1) is a sedative-hypnotic and multiple myeloma medication found to have an inhibitory effect on morning sickness,insomnia, coughs, colds and headaches, but it may lead to severe birth defects if it is taken during pregnancy.

Product Name

Thalidomide

Synthetic route

Thalidomide Chemical Properties

Thalidomide History

Thalidomide Toxicity Data With Reference

Thalidomide Consensus Reports

Thalidomide Safety Profile

Thalidomide Specification

Related Products

Hot Products